Advertisement

Clinical Outcomes After Sirolimus-Eluting, Paclitaxel-Eluting, and Bare Metal Stents (from the First Phase of the Prospective Multicenter German DES.DE Registry)

Published:September 28, 2009DOI:https://doi.org/10.1016/j.amjcard.2009.06.058
      The prospective multicenter German Drug-Eluting Stent (DES.DE) registry is an observational study to analyze and evaluate the therapeutic principle of the differential drug-eluting stents (sirolimus- and paclitaxel-eluting stents) and bare metal stents under real world conditions in the context of the German healthcare system. The baseline clinical and angiographic characteristics and follow-up events for 1 year were recorded for all enrolled patients. In addition, a health economics assessment was performed at 3, 6, 9, and 12 months after initial stent placement. The composite of death, myocardial infarction, and stroke, defined as major adverse cardiac and cerebrovascular events, and target vessel revascularization were used as the primary objectives. From October 2005 to October 2006, 6,384 patients were enrolled (sirolimus-eluting stents, n = 2,137; paclitaxel-eluting stents, n = 2,740; bare metal stents, n = 485) at 98 Deutsches Drug-Eluting Stent Register sites. With similar baseline clinical and descriptive morphology of coronary artery disease between both drug-eluting stent groups, no differences were present at 1 year of follow-up in the rates of overall mortality (3.8% vs 4.1%), target vessel revascularization (10.4% vs 10.4%), overall stent thrombosis (3.6% vs 3.8%), and major adverse cardiac and cerebrovascular events (8.1% vs 8.0%). Compared with the bare metal stent group, patients treated with drug-eluting stents had significantly lower rates of myocardial infarction (3.2% vs 6.0%; p <0.01), stroke (1.2% vs 2.7%; p <0.05), and target vessel revascularization (10.4% vs 14.9%; p <0.01) without any difference in the stent thrombosis rate (3.7% vs 4.3%; p = 0.57) or mortality rate (4.0% vs 5.2%; p = 0.21). In conclusion, the data generated from the German Drug-Eluting Stent registry revealed no differences between patients receiving a paclitaxel-eluting stent and sirolimus-eluting stent in a “real-world” setting with regard to the clinical outcomes at 1 year.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Silber S.
        • Albertson P.
        • Aviles F.F.
        • Camici P.G.
        • Colombo A.
        • Hamm C.
        • Jorgensen E.
        • Marco J.
        • Nordrehaug J.E.
        • Ruzyllo J.E.
        • Urban P.
        • Stone G.W.
        • Wijns W.
        Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.
        Eur Heart J. 2005; 26: 804-847
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • Steg P.E.
        • Morel M.A.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hannon M.
        • Krucoff M.W.
        • Serruys P.W.
        • Academic Research Consortium
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Moses J.W.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerard P.J.
        • Holmes D.R.
        • O'Shaughnessy C.
        • Caputo R.P.
        • Kereiakes D.J.
        • Williams D.O.
        • Teirstein P.S.
        • Jaeger J.L.
        • Kuntz R.E.
        Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
        N Engl J Med. 2003; 349: 1315-1323
        • Stone G.W.
        • Ellis S.G.
        • Cox D.A.
        • Hermiller J.
        • O'Shaughnessy C.
        • Mann J.T.
        • Turco M.
        • Caputo R.
        • Bergin P.
        • Greenberg J.
        • Popma J.J.
        • Russell M.E.
        One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
        Circulation. 2004; 109: 1942-1947
        • Stone G.W.
        • Ellis S.G.
        • Cox D.A.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • Steg P.G.
        • Morel M.A.
        • Mauri L.
        • Vranchx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
        N Engl J Med. 2004; 350: 221-231
        • Grube E.
        • Silber S.
        • Hauptmann K.E.
        • Mueller R.
        • Buellesfeld L.
        • Gerckens U.
        • Russell M.E.
        TAXUS I: six- and twelve month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.
        Circulation. 2003; 107: 38-42
        • Ong A.T.
        • Serruys P.W.
        • Aoki J.
        • Hoye A.
        • van Mieghem C.A.
        • Rodriguez-Granillo G.A.
        • Valgimigli M.
        • Sonnenschein K.
        • Regar E.
        • van der Ent M.
        • de Jaegere P.P.
        • McFadden E.P.
        • Sianos G.
        • van der Giessen W.J.
        • de Feyter P.J.
        • van Domburg R.T.
        The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
        J Am Coll Cardiol. 2005; 45: 1135-1141
        • Morice M.C.
        • Colombo A.
        • Meier B.
        • Serruys P.W.
        • Tamburino C.
        • Guagliumi G.
        • Sousa E.
        • Stoll H.P.
        Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
        JAMA. 2006; 295: 895-904
        • Galloe A.M.
        • Thuesen L.
        • Kelbaek H.
        • Rasmussen K.
        • Hansen P.R.
        • Bligaard N.
        • Saunamäki K.
        • Junker A.
        • Aarge J.
        • Abilgaard U.
        • Ravkilde J.
        • Engstrom T.
        • Jensen J.S.
        • Andersen H.R.
        • Botker H.E.
        • Galatius S.
        • Kristensen S.D.
        • Madsen J.K.
        • Krusell L.R.
        • Abilstrom S.Z.
        • Stephansen G.B.
        • Lassen J.F.
        Comparison of paclitaxel- and sirolimus-eluting stents in every day clinical practice: the SORT OUT II trial.
        JAMA. 2008; 299: 409-416
        • Simonton C.A.
        • Brodie B.
        • Cheek B.
        • Krainin F.
        • Metzger C.
        • Hermiller J.
        • Juk S.
        • Duffy P.
        • Humphrey A.
        • Nussbaum M.
        • Laurent S.
        Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry STENT group.
        J Am Coll Cardiol. 2007; 50: 1214-1222
        • Williams D.O.
        • Abbott D.
        • Kip K.E.
        Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover registry.
        Circulation. 2006; 114: 2154-2162
        • Schömig A.
        • Dibra A.
        • Windecker S.
        • Mehilli J.
        • Suárez de Lezo J.
        • Kaiser C.
        • Park S.J.
        • Goy J.J.
        • Lee J.H.
        • Di Lorenzo E.
        • Wu J.
        • Jüni P.
        • Pfisterer M.E.
        • Meier B.
        • Kastrati A.
        A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
        J Am Coll Cardiol. 2007; 50: 1376-1380
        • Stettler C.
        • Wandel S.
        • Allemann S.
        • Kastrati A.
        • Morice M.C.
        • Schömig A.
        • Pfisterer M.E.
        • Stone G.W.
        • Leon M.B.
        • de Lezo J.S.
        • Goy J.J.
        • Park S.J.
        • Sabate M.
        • Suttorp M.J.
        • Kelbaek H.
        • Spaulding C.
        • Menichelli M.
        • Vermeersch P.
        • Dirksen M.T.
        • Cervinka P.
        • Petronio A.S.
        • Nordmann A.J.
        • Diem P.
        • Meier B.
        • Zwahlen M.
        • Reichenbach S.
        • Trelle S.
        • Windecker S.
        • Jüni P.
        Outcomes associated with drug-eluting and bare-metal stents: a collaborative meta-analysis.
        Lancet. 2007; 370: 937-948
        • Pinto D.S.
        • Stone G.W.
        • Ellis S.G.
        • Cox D.A.
        • Hermiller J.
        • O'Shaughnessy C.
        • Mann J.T.
        • Mehran R.
        • Na Y.
        • Turco M.
        • Caputo R.
        • Popma J.J.
        • Cutlip D.E.
        • Russell M.E.
        • Cohen D.J.
        Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
        J Am Coll Cardiol. 2006; 48: 32-36
        • Morice M.C.
        • Serruys P.W.
        • Sousa E.
        • Fajadet J.
        • Ban Hayashi E.
        • Perin M.
        • Colombo A.
        • Schuler G.
        • Barragan P.
        • Guagliumi G.
        • Molnàr F.
        • Falotico R.
        A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
        N Engl J Med. 2002; 346: 1773-1780
        • Rao S.V.
        • Shaw R.E.
        • Brindis R.G.
        • Klein L.W.
        • Weintraub W.S.
        • Peterson E.D.
        On-versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]).
        Am J Cardiol. 2006; 97: 1478-1481
        • Guagliumi G.
        • Virmani R.
        • Musumeci G.
        • Motta T.
        • Velsecchi O.
        • Bonaldi G.
        • Saino A.
        • Tespili M.
        • Greco N.
        • Farb A.
        Drug-eluting versus bare metal coronary stents: long-term human pathology: finding from different coronary arteries in the same patient.
        Ital Heart J. 2003; 4: 713-720
        • Finn A.V.
        • Kolodgie F.D.
        • Harnek J.
        • Guerrero L.J.
        • Acampado E.
        • Tefera K.
        • Skorija K.
        • Weber D.K.
        • Gold H.K.
        • Virmani R.
        Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.
        Circulation. 2005; 112: 270-278
        • Virmani R.
        • Guagliumi G.
        • Farb A.
        • Musumeci G.
        • Grieco N.
        • Motta T.
        • Mihalcsik L.
        • Tespili M.
        • Valsecchi O.
        • Kolodgie F.D.
        Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?.
        Circulation. 2004; 109: 701-705
        • Degertekin M.
        • Serruys P.W.
        • Tanabe K.
        • Lee C.H.
        • Sousa J.E.
        • Colombo A.
        • Morice M.C.
        • Ligthart J.M.
        • de Freyter P.J.
        Long-term follow-up of incomplete stent apposition in patients who receive the sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis.
        Circulation. 2003; 108: 2747-2750
        • Stone G.W.
        • Moses J.W.
        • Ellis S.G.
        • Schofer J.
        • Dawkins K.D.
        • Morice M.C.
        • Colombo A.
        • Schampaert E.
        • Grube E.
        • Kirtane A.J.
        • Cutlip D.E.
        • Fahy M.
        • Pocock S.J.
        • Mehran R.
        • Leon M.B.
        Safety and efficacy of sirolimus- and paclitaxel eluting coronary stents.
        N Engl J Med. 2007; 356: 998-1008
        • Limpijankit T.
        • Mehran R.
        • Mintz G.S.
        • Dangas G.
        • Lansky A.J.
        • Kao J.
        • Ashby D.T.
        • Moussa I.
        • Stone G.W.
        • Moses J.W.
        • Leon M.B.
        • Teirstein P.S.
        Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-II, and SCRIPPS-III).
        Am J Cardiol. 2003; 92: 315-318
        • Nayak A.K.
        • Kawamura A.
        • Nesto R.W.
        • Davies G.
        • Jarbeau J.
        • Pyne C.T.
        • Gossman D.E.
        • Piemonte T.C.
        • Riskalla C.
        • Chauhan M.S.
        Myocardial infarction as a presentation of clinical in-stent restenosis.
        Circ J. 2006; 70: 1026-1109
        • Walters D.L.
        • Harding S.A.
        • Walsh C.R.
        • Wong P.
        • Pomerantsev E.
        • Jang I.K.
        Acute coronary syndrome is a common clinical presentation of in-stent restenosis.
        Am J Cardiol. 2002; 89: 491-494
        • Sousa A.
        • Costa R.
        • Moreira A.C.
        • Cano M.
        • Maldonado G.
        • Costa R.A.
        • Pavanello R.
        • Romano E.R.
        • Campos C.
        • Haddad N.
        • Abizaid A.
        • Feres F.
        • Mattos L.A.
        • Staico R.
        • Sousa J.E.
        Long-term clinical outcomes of drug-eluting stents in the real-world (DESIRE) registry.
        J Interv Cardiol. 2008; 21: 307-314
        • Marzocchi A.
        • Saia F.
        • Piovaccari G.
        • Manari A.
        • Aurier E.
        • Benassi A.
        • Cremonesi A.
        • Percoco G.
        • Virmani E.
        • Magnavacchi P.
        • Guastaroba P.
        • Grilli R.
        • Maresta A.
        Long-term safety and efficacy of drug-eluting stents.
        Circulation. 2007; 115: 3181-3188